Improved Financial Metrics
Adjusted EBITDA margins expected to expand approximately 600 basis points from 2023 to year-end. Year-to-date, free cash flow improved by $20 million, and debt reduced by $35 million, reducing net leverage by more than 2 turns.
Successful Cost Optimization
Cost optimization initiatives resulted in adjusted EBITDA margin of 18.9% for Q3 2025, marking a 155 basis point improvement compared to the previous year.
Cash Flow and Leverage Improvements
Cash balance increased from $3.8 million at the end of 2023 to approximately $20 million. Free cash flow was $15 million year-to-date in 2025 compared to a cash outflow of $5 million in 2023.
Revenue Growth in Patient Care
Patient Care revenue grew 5.3% year-over-year, driven by SaaS growth and nonrecurring revenues. Excluding Centriq, growth in Patient Care revenue would have been 8.9%.
Positive Outlook for Future
Anticipated 200 basis points of EBITDA margin expansion in 2026 due to ongoing cost optimizations and global workforce transitions.